“But you should think about the operating margin as a floor as we look forward through ’25.”

In context

“sense of kind of the path to 2025 as we move through the balance of this year and next year. Thanks. David Elkins: Yes, thanks, Seamus, for the question. And the 37% guidance is a floor that we’ve provided as we look forward to that midterm period, which is 2025. We haven’t provided guidance yet. We’ll do that on the fourth quarter earnings call as it relates to 2024, which I think is what your question is getting after. I’d say the one thing to think about is, one, we’ve talked about Revlimid in the past and we’ve said, we’ve revised Revlimid’s guidance this year from $5.5 billion to $6 billion, and we still see next year stepping down to about that $4 billion, and then we’ll update you on all the other line items when we do our fourth quarter earnings as far as profitability next year. But you should think about the operating margin as a floor as we look forward through ’25. Tim Power: Thanks, David, and thanks for the question, Seamus. Keith, can we go to the next question, please? Operator: Certainly, and that comes from Chris Shibutani with Goldman Sachs. Chris Shibutani: Thank you very much. You’ve made some comments about Sotyktu and the reimbursement environment as that is evolving, and the constraints that you have. Perhaps for Adam or whomever would be appropriate, could you comment further about what you’re seeing there and how we should be thinking about the cadence? I think the set-up had been that ’24 would be an opportunity, and that seems to be slightly different. Adam Lenkowsky: Chris, thank you for the question. First, I want to say we’re very pleased with the performance of Sotyktu. Our goal remains to be the standard of care in the oral ma”